Surviving childhood cancer: The impact on life

Pediatric Drugs

Volumn 8, Issue 2, 2006, Pages 71-84

  Goldsby, Robert E ^a,b   Taggart, Denah R ^a   Ablin, Arthur R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GROWTH HORMONE; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NITROSOUREA; PROCARBAZINE; TENIPOSIDE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE;

ACADEMIC ACHIEVEMENT; ACOUSTIC NEURINOMA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOMATOUS POLYP; ADONTIA; ADRENAL CORTEX TUMOR; ARTIFICIAL HEART PACEMAKER; ATAXIA TELANGIECTASIA; AZOOSPERMIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BLOOM SYNDROME; BONE DISEASE; BONE MARROW TRANSPLANTATION; BRAIN FUNCTION; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOMA; CARDIOMYOPATHY; CARDIOTOXICITY; CATARACT; CHILD GROWTH; CHILD HEALTH; CHILD PSYCHOLOGY; CHILDHOOD CANCER; COGNITIVE DEFECT; COLON CANCER; COLORECTAL CANCER; COUGHING; DENTAL CARIES; DENYS DRASH SYNDROME; DEVELOPMENTAL DISORDER; DIPLOPIA; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; DRUG INDUCED CANCER; DRUG MEGADOSE; DYSPNEA; EARLY DIAGNOSIS; EARLY MENOPAUSE; ENDOCRINE DISEASE; ENOPHTHALMOS; EYE INJURY; EYE TOXICITY; FAMILIAL CANCER; FANCONI ANEMIA; FANCONI RENOTUBULAR SYNDROME; FEMALE INFERTILITY; FOLLOW UP; FRACTURE; GENETIC DISORDER; GINGIVITIS; GLIOBLASTOMA; GONAD FUNCTION; GROWTH HORMONE DEFICIENCY; HEARING DISORDER; HEARING LOSS; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPODONTIA; HYPOPLASIA; KERATOCONJUNCTIVITIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FUNCTION; LIVER INJURY; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; LUNG TOXICITY; MALE INFERTILITY; MEDULLOBLASTOMA; MELANOMA; MENINGIOMA; MENTAL DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; MYELOID LEUKEMIA; NEPHROBLASTOMA; NEPHROTOXICITY; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUROSURGERY; NONHODGKIN LYMPHOMA; OBESITY; OLIGOSPERMIA; OPTIC NERVE GLIOMA; OSTEOPOROSIS; OSTEOSARCOMA; OTOTOXICITY; PANCREAS ISLET CELL TUMOR; PATIENT CARE; PATIENT MONITORING; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RETINOBLASTOMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SECOND CANCER; SEXUAL MATURATION; SHORT STATURE; SKIN CARCINOMA; SOFT TISSUE CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; TOOTH DISEASE; TOOTH ROOT SHUNTING; TURCOT SYNDROME; VISUAL DISORDER; VITAL CAPACITY; VON HIPPEL LINDAU DISEASE; WAGR SYNDROME; WHOLE BODY RADIATION; XERODERMA PIGMENTOSUM;

ANTINEOPLASTIC AGENTS; BONE AND BONES; CARDIOVASCULAR PHYSIOLOGY; CHILD; HUMANS; KIDNEY; LIVER; LUNG; MUSCULOSKELETAL PHYSIOLOGY; NEOPLASMS; QUALITY OF LIFE; SENSATION; SURVIVAL; TOOTH;

EID: 33645860185     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608020-00001     Document Type: Review

References (198)

1. Ries L, Eisner M, Kosary C, et al. SEER cancer statistics review 1975-2002. Bethesda (MD): National Cancer Institute, 2003. Also available online from URL: http://seer.cancer.gov/csr/1975_2002 [Accessed 2005]
2. Bhatia S, Meadows A. Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatr Blood Cancer 2006; 46 (2): 143-8
3. Hewitt M, Wiener S, Si Mone JV, editors. Childhood cancer survivorship: improving care and quality of life. National Cancer Policy Board. Washington, DC: National Academics Press, 2003
4. Ablin AR. Supportive care of children with cancer: current therapy and guidelines from the Children's Cancer Group. 2nd ed. Baltimore (MD): The Johns Hopkins University Press, 1997
5. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002
6. Kubota M, Lin YW, Hamahata K, et al. Cancer chemotherapy and somatic cell mutation. Mutat Res 2000; 470 (2): 93-102
7. Dempsey JL, Seshadri RS, Morley AA. Increased mutation frequency following treatment with cancer chemotherapy. Cancer Res 1985; 45 (6): 2873-7
8. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003; 100 (3): 776-81
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1): 57-70
10. Langeveld NE, Ubbink MC, Last BF, et al. Educational achievement, employment and living situation in long-term young adult survivors of childhood cancer in the Netherlands. Psychooncology 2003; 12 (3): 213-25
11. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349 (7): 640-9
12. Garre ML, Gandus S, Cesana B, et al. Health status of long-term survivors after cancer in childhood: results of an uniinstitutional study in Italy. Am J Pediatr Hematol Oncol 1994; 16 (2): 143-52
13. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290 (12): 1583-92
14. Lackner H, Benesch M, Schagerl S, et al. Prospective evaluation of late effects after childhood cancer therapy with a follow-up over 9 years. Eur J Pediatr 2000; 159 (10): 750-8
15. Humpl T, Fritsche M, Bartels U, et al. Survivors of childhood cancer for more than twenty years. Acta Oncol 2001; 40 (1): 44-9
16. Pastore G, Mosso ML, Magnani C, et al. Physical impairment and social life goals among adult long-term survivors of childhood cancer: a population-based study from the childhood cancer registry of Piedmont, Italy. Tumori 2001; 87 (6): 372-8
17. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19 (13): 3163-72
18. Frei III E, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965; 26 (5): 642-56
19. Hudson MM, Jones D, Boyett J, et al. Late mortality of long-term survivors of childhood cancer. J Clin Oncol 1997; 15 (6): 2205-13
20. Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001; 19 (13): 3173-81
21. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ 1994; 309 (6948): 162-6
22. Jazbec J, Ecimovic P, Jereb B. Second neoplasms after treatment of childhood cancer in Slovenia. Pediatr Blood Cancer 2004; 42 (7): 574-81
23. Robison LL, Mertens A. Second tumors after treatment of childhood malignancies. Hematol Oncol Clin North Am 1993; 7 (2): 401-15
24. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93 (8): 618-29
25. Wong FL, Boice Jr JD, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 1997; 278 (15): 1262-7
26. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology 2001; 108 (6): 1109-14
27. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88 (4): 672-8
28. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21 (23): 4386-94
29. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334 (12): 745-51
30. Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc 2003; 78 (6): 708-15
31. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000; 26 (4): 291-302
32. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85 (9): 3227-32
33. Inskip PD. Thyroid cancer after radiotherapy for childhood cancer. Med Pediatr Oncol 2001; 36 (5): 568-73
34. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001; 36 (5): 525-35
35. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol 1994; 22 (1): 1-10
36. Klein G, Michaelis J, Spix C, et al. Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer 2003; 39 (6): 808-17
37. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003; 21 (6): 1074-81
38. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodys-plastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17 (2): 569-77
39. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001; 19 (6): 1610-8
40. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18 (3): 498-509
41. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18 (3): 487-97
42. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18 (12): 2435-43
43. de Vathaire F, Hawkins M, Campbell S, et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 1999; 79 (11-12): 1884-93
44. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87 (20): 1530-7
45. Giovannucci E. Alcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies. J Nutr 2004; 134 (9): 2475S-81S
46. Cutuli B, Borel C, Dhermain F, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 2001; 59 (3): 247-55
47. Diller L, Medeiros Nancarrow C, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2002; 20 (8): 2085-91
48. Wolden SL, Hancock SL, Carlson RW, et al. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000; 18 (4): 765-72
49. Gow KW, Lensing S, Hill DA, et al. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature. J Pediatr Surg 2003; 38 (11): 1574-80
50. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003; 21 (17): 3255-61
51. Sonderkaer S, Schmiegelow M, Carstensen H, et al. Long-term neurological outcome of childhood brain tumors treated by surgery only. J Clin Oncol 2003; 21 (7): 1347-51
52. Syndikus I, Tait D, Ashley S, et al. Long-term follow-up of young children with brain tumors after irradiation. Int J Radiat Oncol Biol Phys 1994; 30 (4): 781-7
53. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003; 97 (3): 663-73
54. Ross L, Johansen C, Dalton SO, et al. Psychiatric hospitalizations among survivors of cancer in childhood or adolescence. N Engl J Med 2003; 349 (7): 650-7
55. Butler RW, Copeland DR. Neuropsychological effects of central nervous system prophylactic treatment in childhood leukemia: methodological considerations. J Pediatr Psychol 1993; 18 (3): 319-38
56. Meadows AT, Gordon J, Massari DJ, et al. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 1981; II (8254): 1015-8
57. Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998; 82 (1): 208-18
58. Waber DP, Shapiro BL, Carpentieri SC, et al. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 2001; 92 (1): 15-22
59. Smibert E, Anderson V, Godber T, et al. Risk factors for intellectual and educational sequelae of cranial irradiation in childhood acute lymphoblastic leukaemia. Br J Cancer 1996; 73 (6): 825-30
60. Waber DP, Tarbell NJ, Fairclough D, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 1995; 13 (10): 2490-6
61. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia: ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 1994; 344 (8917): 224-7
62. Moore IM, Kramer JH, Wara W, et al. Cognitive function in children with leukemia: effect of radiation dose and time since irradiation. Cancer 1991; 68 (9): 1913-7
63. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003; 21 (9): 1798-809
64. Kingma A, van Dommelen RI, Mooyaart EL, et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001; 139 (3): 413-20
65. Kingma A, Van Dommelen RI, Mooyaart EL, et al. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol 2002; 24 (2): 106-14
66. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14 (12): 2257-66
67. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124 (1): 33-46
68. Noll RB, Gartstein MA, Vannatta K, et al. Social, emotional, and behavioral functioning of children with cancer. Pediatrics 1999; 103 (1): 71-8
69. Glover DA, Byrne J, Mills JL, et al. Impact of CNS treatment on mood in adult survivors of childhood leukemia: a report from the Children's Cancer Group. J Clin Oncol 2003; 21 (23): 4395-401
70. Langeveld N, Ubbink M, Smets E. 'I don't have any energy': the experience of fatigue in young adult survivors of childhood cancer. Eur J Oncol Nurs 2000; 4 (1): 20-8
71. Langeveld NE, Grootenhuis MA, Voute PA, et al. No excess fatigue in young adult survivors of childhood cancer. Eur J Cancer 2003; 39 (2): 204-14
72. Noorda EM, Somers R, van Leeuwen FE, et al. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer 2001; 37 (5): 605-12
73. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology 1975; 114 (1): 155-62
74. Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab 2003; 88 (10): 4731-9
75. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002; 16 (4): 225-43
76. Shalet SM, Brennan BM. Growth and growth hormone status following treatment for childhood leukaemia. Horm Res 1998; 50 (1): 1-10
77. Birkebaek NH, Clausen N. Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1998; 79 (2): 161-4
78. Holm K, Nysom K, Hertz H, et al. Normal final height after treatment for acute lymphoblastic leukemia without irradiation. Acta Paediatr 1994; 83 (12): 1287-90
79. Dalton VK, Rue M, Silverman LB, et al. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol 2003; 21 (15): 2953-60
80. Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122 (3): 345-59
81. Sklar C, Mertens A, Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr 1993; 123 (1): 59-64
82. Cicognani A, Cacciari E, Rosito P, et al. Longitudinal growth and final height in long-term survivors of childhood leukaemia. Eur J Pediatr 1994; 153 (10): 726-30
83. Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17 (1): 55-66
84. Cohen LE. Endocrine late effects of cancer treatment. Endo Metab Clin North Am 2005; 34 (3): 769-80
85. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003; 88 (8): 3682-9
86. Gleeson HK, Shalet SM. Endocrine complications of neoplastic diseases in children and adolescents. Curr Opin Pediatr 2001; 13 (4): 346-51
87. Murray RD, Darzy KH, Gleeson HK, et al. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab 2002; 87 (1): 129-35
88. Leung W, Rose SR, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2002; 20 (13): 2959-64
89. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85 (12): 4444-9
90. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87 (7): 3136-41
91. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19 (2): 480-7
92. Lustig RH, Post SR, Srivannaboon K, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003; 88 (2): 611-6
93. Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21 (7): 1359-65
94. Didi M, Didcock E, Davies HA, et al. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995; 127 (1): 63-7
95. Warner JT, Evans WD, Webb DK, et al. Body composition of long-term survivors of acute lymphoblastic leukaemia. Med Pediatr Oncol 2002; 38 (3): 165-72
96. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003; 88 (6): 2586-92
97. Reilly JJ, Ventham JC, Ralston JM, et al. Reduced energy expenditure in preobese children treated for acute lymphoblastic leukemia. Pediatr Res 1998; 44 (4): 557-62
98. Reilly JJ, Kelly A, Ness P, et al. Premature adiposity rebound in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001; 86 (6): 2775-8
99. van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab 2003; 88 (8): 3657-63
100. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, et al. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab 2003; 88 (7): 3149-54
101. Cicognani A, Pasini A, Pession A, et al. Gonadal function and pubertal development after treatment of a childhood malignancy. J Pediatr Endocrinol Metab 2003; 16 Suppl. 2: 321-6
102. Muller J. Disturbance of pubertal development after cancer treatment. Best Pract Res Clin Endocrinol Metab 2002; 16 (1): 91-103
103. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999; 150 (3): 245-54
104. Larsen EC, Muller J, Schmiegelow K, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003; 88 (11): 5307-14
105. Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987; 317 (21): 1315-21
106. Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 1981; 139 (1): 62-6
107. Teinturier C, Hartmann O, Valteau-Couanet D, et al. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998; 22 (10): 989-94
108. Thibaud E, Rodriguez-Macias K, Trivin C, et al. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998; 21 (3): 287-90
109. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999; 33 (1): 29-33
110. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002; 187 (4): 1070-80
111. Green DM, Zevon MA, Lowrie G, et al. Congenital anomalies in children of patients who received chemotherapy for cancer in childhood and adolescence. N Engl J Med 1991; 325 (3): 141-6
112. Green DM, Fiorello A, Zevon MA, et al. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997; 151 (4): 379-83
113. Mustieles C, Munoz A, Alonso M, et al. Male gonadal function after chemotherapy in survivors of childhood malignancy. Med Pediatr Oncol 1995; 24 (6): 347-51
114. Colpi GM, Contalbi GF, Nerva F, et al. Testicular function following chemoradiotherapy. Eur J Obstet Gynecol Reprod Biol 2004; 113 Suppl. 1: S2-6
115. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21 (4): 716-21
116. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001; 91 (3): 613-21
117. Heikens J, Behrendt H, Adriaanse R, et al. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer 1996; 78 (9): 2020-4
118. Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect 1993; 101 Suppl. 2: 109-16
119. Byrne J, Fears TR, Mills JL, et al. Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood. Pediatr Blood Cancer 2004; 42 (7): 589-97
120. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32 (2): 302-14
121. Bristow MR, Billingham ME, Mason JW, et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62 (6): 873-9
122. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthra-cycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16 (2): 545-50
123. Ewer MS, Jaffe N, Ried H, et al. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 1998; 31 (6): 512-5
124. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266 (12): 1672-7
125. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97 (8): 1991-8
126. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91 (5): 710-7
127. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19 (1): 191-6
128. Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21 (12): 2349-56
129. Minow RA, Benjamin RS, Lee ET, et al. Adriamycin cardiomyopathy: risk factors. Cancer 1977; 39 (4): 1397-402
130. Billingham ME, Bristow MR, Glatstein E, et al. Adriamycin cardiotoxicity: endo-myocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977; 1 (1): 17-23
131. Bar J, Davidi O, Goshen Y, et al. Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 2003; 189 (3): 853-7
132. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20 (23): 4517-22
133. Gupta M, Steinherz PG, Cheung NK, et al. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003; 40 (6): 343-7
134. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8 Suppl. 2: 17-24
135. Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin Oncol 1998; 25 (4 Suppl. 10): 86-92
136. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14 (2): 362-72
137. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 1991; 33 (5): 299-311
138. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290 (21): 2831-7
139. Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003; 13 (3): 346-56
140. Constine LS, Schwartz RG, Savage DE, et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; 39 (4): 897-906
141. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22 (5): 820-8
142. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89 (5 Pt 1): 942-9
143. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001; 13 (4): 242-8
144. Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer 2002; 95 (11): 2431-41
145. Nysom K, Holm K, Olsen JH, et al. Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood. Br J Cancer 1998; 78 (1): 21-7
146. Fulgoni P, Zoia MC, Corsico A, et al. Lung function in survivors of childhood acute lymphoblastic leukemia. Chest 1999; 116 (5): 1163-7
147. Ellis ER, Marcus Jr RB, Cicale MJ, et al. Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma. J Clin Oncol 1992; 10 (3): 459-63
148. Kaplan E, Sklar C, Wilmott R, et al. Pulmonary function in children treated for rhabdomyosarcoma. Med Pediatr Oncol 1996; 27 (2): 79-84
149. Kharasch VS, Lipsitz S, Santis W, et al. Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors. Med Pediatr Oncol 1996; 27 (2): 85-91
150. Lund MB, Kongerud J, Nome O, et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6 (5): 495-501
151. Bossi G, Cerveri I, Volpini E, et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 1997; 8 Suppl. 1: 19-24
152. Cerveri I, Zoia MC, Fulgoni P, et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54 (2): 131-5
153. Cerveri I, Fulgoni P, Giorgiani G, et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest 2001; 120 (6): 1900-6
154. Neve V, Foot AB, Michon J, et al. Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation, and autologous bone marrow transplantation for metastatic neuroblastoma. Med Pediatr Oncol 1999; 32 (3): 170-6
155. Nenadov Beck M, Meresse V, Hartmann O, et al. Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation. Bone Marrow Transplant 1995; 16 (6): 771-5
156. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. Chest 1997; 111 (4): 1061-76
157. Hansen SW, Groth S, Sorensen PG, et al. Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. Eur J Cancer Clin Oncol 1989; 25 (4): 733-6
158. Kakihara T, Imai C, Hotta H, et al. Impaired tubular excretory function as a late renal side effect of chemotherapy in children. J Pediatr Hematol Oncol 2003; 25 (3): 209-14
159. Suarez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 1991; 9 (12): 2177-82
160. Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76 (12): 2557-64
161. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999; 39 (5): 454-61
162. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41 (3): 190-7
163. Liesner RJ, Leiper AD, Hann IM, et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994; 12 (5): 916-24
164. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26 (2): 75-80
165. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5 (8): 1191-8
166. Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Huntingt) 1991; 5 (10): 97-102, 105
167. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 1990; 17 (2 Suppl. 4): 68-73
168. Halonen P, Mattila J, Ruuska T, et al. Liver histology after current intensified therapy for childhood acute lymphoblastic leukemia: microvesicular fatty change and siderosis are the main findings. Med Pediatr Oncol 2003; 40 (3): 148-54
169. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93 (10): 3259-66
170. Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol 2003; 41 (3): 198-207
171. Henderson RC, Madsen CD, Davis C, et al. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol 1996; 18 (4): 367-71
172. Kadan-Lottick N, Marshall JA, Baron AE, et al. Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr 2001; 138 (6): 898-904
173. Aisenberg J, Hsieh K, Kalaitzoglou G, et al. Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 1998; 20 (3): 241-5
174. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15 (5): 728-34
175. Hosalkar HS, Dormans JP. Limb sparing surgery for pediatric musculoskeletal tumors. Pediatr Blood Cancer 2004; 42 (4): 295-310
176. Tomita K, Tsuchiya H. Intermediate results and functional evaluation of limb-salvage surgery for osteosarcoma: an intergroup study in Japan. J Surg Oncol 1989; 41 (2): 71-6
177. Nagarajan R, Neglia JP, Clohisy DR, et al. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 2002; 20 (22): 4493-501
178. Refaat Y, Gunnoe J, Hornicek FJ, et al. Comparison of quality of life after amputation or limb salvage. Clin Orthop Relat Res 2002 Apr; (397): 298-305
179. Rougraff BT, Simon MA, Kneisl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994; 76 (5): 649-56
180. Hudson MM, Tyc VL, Cremer LK, et al. Patient satisfaction after limb-sparing surgery and amputation for pediatric malignant bone tumors. J Pediatr Oncol Nurs 1998; 15 (2): 60-9
181. Postma A, Kingma A, De Ruiter JH, et al. Quality of life in bone tumor
182. Ham SJ, Schraffordt Koops H, Veth RP, et al. Limb salvage surgery for primary bone sarcoma of the lower extremities: long-term consequences of endoprosthetic reconstructions. Ann Surg Oncol 1998; 5 (5): 423-36
183. Grimer RJ, Carter SR, Pynsent PB. The cost-effectiveness of limb salvage for bone tumours. J Bone Joint Surg Br 1997; 79 (4): 558-61
184. Hopewell JW. Radiation-therapy effects on bone density. Med Pediatr Oncol 2003; 41 (3): 208-11
185. Maguire A, Craft AW, Evans RG, et al. The long-term effects of treatment on the dental condition of children surviving malignant disease. Cancer 1987; 60 (10): 2570-5
186. Duggal MS, Curzon ME, Bailey CC, et al. Dental parameters in the long-term survivors of childhood cancer compared with siblings. Oral Oncol 1997; 33 (5): 348-53
187. Kaste SC, Hopkins KP, Jones D, et al. Dental abnormalities in children treated for acute lymphoblastic leukemia. Leukemia 1997; 11 (6): 792-6
188. Nasman M, Forsberg CM, Dahllof G. Long-term dental development in children after treatment for malignant disease. Eur J Orthod 1997; 19 (2): 151-9
189. Duggal MS. Root surface areas in long-term survivors of childhood cancer. Oral Oncol 2003; 39 (2): 178-83
190. Jaffe N, Toth BB, Hoar RE, et al. Dental and maxillofacial abnormalities in long-term survivors of childhood cancer: effects of treatment with chemotherapy and radiation to the head and neck. Pediatrics 1984; 73 (6): 816-23
191. van Kempen-Harteveld ML, Struikmans H, Kal HB, et al. Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment. Int J Radiat Oncol Biol Phys 2002; 52 (5): 1375-80
192. Wilde G, Sjostrand J. A clinical study of radiation cataract formation in adult life following gamma irradiation of the lens in early childhood. Br J Ophthalmol 1997; 81 (4): 261-6
193. Raney RB, Anderson JR, Kollath J, et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdo-myosarcoma Study (IRS)-III, 1984-1991. Med Pediatr Oncol 2000; 34 (6): 413-20
194. Miettinen S, Laurikainen E, Johansson R, et al. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl 1997; 529: 90-4
195. Weatherly RA, Owens JJ, Catlin FI, et al. cis-platinum ototoxicity in children. Laryngoscope 1991; 101 (9): 917-24
196. Johannesen TB, Rasmussen K, Winther FO, et al. Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 2002; 53 (1): 86-90
197. Notteghem P, Soler C, Dellatolas G, et al. Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation. Bone Marrow Transplant 2003; 31 (7): 599-606
198. Goldsby RE, Ablin AR. Surviving childhood cancer; now what? Controversies regarding long-term follow-up. Pediatr Blood Cancer 2004; 43 (3): 211-4